CliffBio
small molecule

OVIDE

MALATHION

Loss of exclusivityFebruary 2027latest FDA-listed patent expiry
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameOVIDE
Active ingredientMALATHION
Strength0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formLOTION
RouteTOPICAL
ModalitySmall molecule
FDA approvalAugust 1982
Marketing statusDISCN

Listed patents

PatentExpiresType
7560445February 2027substance, product
7977324August 2026product

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OVIDE patent cliff — loss of exclusivity February 2027 | CliffBio